Summary
Differentials
Common
- Induzida por bebidas alcoólicas
- Esteatose hepática
- Colangite biliar primária (CBP)
- Colangite esclerosante primária
- Hemocromatose
- Linfoma de Hodgkin
- Linfoma não Hodgkin (LNH)
- Macroglobulinemia de Waldenström ou linfoma linfoplasmacítico
- Leucemia mieloide aguda (LMA)
- Leucemia mieloide crônica (LMC)
- Leucemia linfoide aguda (LLA)
- Leucemia linfocítica crônica (LLC)
- Leucemia de células pilosas
- Mielofibrose
- Policitemia vera
- Trombocitose essencial
- Metástases esplênicas
- Anemia hemolítica autoimune
- Artrite reumatoide (AR)
- Síndrome de Felty
- Lúpus eritematoso sistêmico
- Sarcoidose
- Malária
- Vírus Epstein-Barr (EBV)
- Endocardite
- Abscessos esplênicos relacionados à sepse
- Hepatite C crônica
- Hepatite B crônica
- Anemia falciforme
- Defeitos citoesqueléticos
- Talassemias
Uncommon
- Tumores esplênicos benignos
- Trombose da veia porta
- Trombose da veia esplênica
- Síndrome de Budd-Chiari
- Linfo-histiocitose hemofagocítica (LHH)
- Amiloidose
- Doença de Gaucher ou de Niemann-Pick
- Dengue grave
- Ruptura esplênica
- Hemorragia subcapsular
- Secundária ao fator estimulador de colônias de granulócitos (G-CSF)
Contributors
Authors
Terri L. Parker, MD
Assistant Professor of Medicine
Section of Hematology
Yale School of Medicine
Smilow Cancer Center at Yale-New Haven
New Haven
CT
Disclosures
TLP declares that she has no competing interests.
Acknowledgements
Dr Terri L. Parker would like to gratefully acknowledge Dr Alan E. Lichtin, the previous contributor to this monograph.
Disclosures
AEL has received research support from Amgen.
Peer reviewers
Priyanka Mehta, MD
Consultant Haematologist
Bristol Haematology and Oncology Centre
Bristol
UK
Disclosures
PM declares that she has no competing interests.
Ruben A. Mesa, MD
Professor of Medicine
Mayo Clinic
Scottsdale
AZ
Disclosures
RAM declares that he has no competing interests.
Giovanni Barosi, MD
Director of the Laboratory of Clinical Epidemiology
IRCCS Policlinico S. Matteo Foundation
Pavia
Italy
Disclosures
GB declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-58.Full text Abstract
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.Full text Abstract
Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023 Oct;82(10):1271-85.Full text Abstract
Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Guidelines
- ACR appropriateness criteria: acute left upper quadrant pain
- WHO Guidelines for malaria
More GuidelinesPatient information
Linfoma não Hodgkin
Hepatite C: o que é?
More Patient information
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer